Essix Biosciences Limited, a active public limited company, was established on 24 September 1993 in Chandigarh, Chandigarh, India. Engaging in drug formulation & development within the manufacturing sector, it holds CIN: U74999CH1993PLC033428. Registered under ROC Roc Chandigarh. it is unlisted. It has an authorized capital of ₹27.37 Cr and a paid-up capital of ₹14.81 Cr.
It upholds a compliant status. Employing 80 professional, Its leadership includes Subhash Chander Galhotra (Director), Rishav Mehta (Director), Navrattan Munjal (Managing Director). Past directors included Gopal Munjal, Sanjeev Rai Mehta, Sunita Jain. It holds ₹4.20 Cr open charges and ₹1,638.83 Cr settled loans. Its latest AGM occurred on 30 September 2024, with the balance sheet filed on 31 March 2024. It is based at Sco 850, Shivalik Enclave,, Chandigarh, Chandigarh, 160101.
U74999CH1993PLC033428
033428
24 September 1993
₹27.37 Cr
₹14.81 Cr
Roc Chandigarh
Unlisted
Active
Explore comprehensive insights into Essix Biosciences Limited — covering financial performance, compliance records, Competitor, shareholding patterns, directors, key metrics, and litigation history. Unlock to see detailed insights and stay informed.
Access Report
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Subhash Chander Galhotra | Director | 31 Mar 2015 | Current |
| Rishav Mehta | Director | 23 Mar 2010 | Current |
| Navrattan Munjal | Managing Director | 24 Sep 1993 | Current |
| Prabhat Khurana | Director | 21 Dec 2021 | Current |
| Himanshu Jain | Director | 27 Aug 2008 | Current |
| Name | Designation | Cessation | Status |
|---|---|---|---|
| Pramod Abcsdd | Director | 05 Apr 2019 | Past |
| Pramod Abcsdd | Director | 05 Apr 2019 | Past |
| Pramod Abcsdd | Director | 12 May 2014 | Past |
| Pramod Abcsdd | Director | 05 Apr 2019 | Past |
| Pramod Abcsdd | Company Secretary | 22 Jul 2016 | Past |
| Pramod Abcsdd | Director | 01 May 2019 | Past |
Discover detailed profiles of directors and KMP - Unlock leadership insights today!
Essix Biosciences Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 16.1% decrease. The company also saw a substantial improvement in profitability, with a 133.64% increase in profit. The company's net worth moved up by a moderate rise of 0.36%.
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
In 2023, Essix Biosciences had a promoter holding of 77.69% and a public holding of 22.31%. The company had 2 Subsidiaries and 2 Associate Companies. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Reveal ownership structures and financial performance - Get instant access now!
₹42,000,000.00
₹16,388,300,000.00
| Date | Lender | Amount | Status |
|---|---|---|---|
| 30 Jun 2025 | Others | ₹2.00 Cr | Open |
| 25 Feb 2022 | Others | ₹2.00 M | Open |
| 21 Dec 2021 | Others | ₹1.00 Cr | Open |
| 21 Dec 2021 | Others | ₹1.00 Cr | Open |
| 31 Jul 2020 | Idbi Bank Limited | ₹2.30 Cr | Satisfied |
Explore comprehensive loan charge details -
Essix Biosciences has a workforce of 80 employees as of Apr 07, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Gain comprehensive insights into the Deals and Valuation data of Essix Biosciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Essix Biosciences's trajectory.
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
The activity Reetika Tanwar was appointed as a Company Secretary was appointed as a Company Secretary on 14 Aug 2025 & has been associated with this company since 4 months 3 days . was completed.
A charge with Others amounted to Rs. 2.00 Cr with Charge ID 101129533 was registered on 30 Jun 2025. was recorded as a recent event.
The activity Essix Biosciences Limited last Annual general meeting of members was held on 30 Sep 2024 as per latest MCA records. was completed.
The activity Essix Biosciences Limited has filed its annual Financial statements for the year ended 31 Mar 2024 with Roc Chandigarh. was completed.
Progress on A charge registered on 31 Jul 2020 via Charge ID 100363957 with Idbi Bank Limited was fully satisfied on 13 Feb 2024. was documented.
The activity A charge registered on 29 Aug 2008 via Charge ID 10119108 with Idbi Bank Limited was fully satisfied on 13 Feb 2024. was completed.
The CIN of Essix Biosciences Limited is U74999CH1993PLC033428.
Essix Biosciences Limited is headquartered at Sco 850, Shivalik Enclave,, Chandigarh, Chandigarh, 160101.
Essix Biosciences Limited was incorporated on 24 September 1993.
The current directors of Essix Biosciences Limited are
The primary industry of Essix Biosciences Limited is Manufacturing.
Essix Biosciences Limited is unlisted.
The authorized capital of Essix Biosciences Limited is ₹27.37 Cr, and the paid-up capital is ₹14.81 Cr.
The compliance status of Essix Biosciences Limited is Compliant.
Search company & director profiles for free and gain access to critical business data.
Company Details
+91-XXXXXXXXXX